<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Dowsett, Mitchell</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Highlights and Future Directions in AI Clinical Research</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-16</style></pages><abstract><style  face="normal" font="default" size="100%">Aromatase inhibitors are important agents used for the adjuvant treatment of early hormone receptor-positive breast cancer in postmenopausal women. Studies in early stage breast cancer are ongoing to determine if the cellular proliferation biomarker Ki67 predicts patient response to therapy. Genetic analysis of biopsy specimens may help identify resistance mechanisms.</style></abstract><number><style face="normal" font="default" size="100%">56</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>